Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition of the CoMET platform significantly enhances and expands VectivBio’s pipeline including VB-1197, being evaluated in methylmalonic acidemia (MMA) and propionic acidemia (PA), two organic acidemias result in severe neurological disability in adult survivors.
Lead Product(s): VB-1197
Therapeutic Area: Genetic Disease Product Name: VB-1197
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: VectivBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 21, 2021